Predictive value of recurrence of solid and micropapillary subtype in lung adenocarcinoma

被引:1
作者
Motono, Nozomu [1 ]
Mizoguchi, Takaki [1 ]
Ishikawa, Masahito [1 ]
Iwai, Shun [1 ]
Iijima, Yoshihito [1 ]
Uramoto, Hidetaka [1 ]
机构
[1] Kanazawa Med Univ, Dept Thorac Surg, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan
关键词
histological subtype; solid; micropapillary; lung adenocarcinoma; recurrence; PROGNOSTIC NUTRITIONAL INDEX; INTERNATIONAL-ASSOCIATION; ADJUVANT CHEMOTHERAPY; STAGE-I; CLASSIFICATION; CANCER; SURVIVAL;
D O I
10.1159/000530528
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Although histological subtype in lung adenocarcinoma has been reported as a poor prognostic factor in several studies, its utility has not yet been revealed as an adaptation criterion of postoperative adjuvant chemotherapy.Materials: Four hundred ninety-four lung adenocarcinoma patients were enrolled in this retrospective study. A sub-analysis was performed in 420 lung adenocarcinoma patients with pathological stage 0-I disease for risk factors of postoperative recurrence.Results: Maximum standardized uptake value (SUVmax) (p<0.01), pathological stage >= II (p<0.04), and adjuvant chemotherapy (p<0.01) were risk factors for recurrence in the multivariate analysis, whereas histological subtype was not a significant factor for recurrence at all stages. In the sub-analysis, univariate analysis showed that carcinoembryonic antigen expression (p<0.01), prognostic nutrition index (p=0.03), SUVmax (p<0.01), lymphatic invasion (p<0.01), vascular invasion (p<0.01), grade 3-4 differentiation (p<0.01), pathological stage >= IA3 (p<0.01), and histological subtype (p=0.03) were significant risk factors of recurrence. SUVmax (p<0.01) was the only risk factor for recurrence in the multivariate analysis, whereas histological subtype was not (p=0.07). Relapse-free survival (RFS) was significantly worse in the micropapillary- and solid-predominant subtype groups than in the other subtypes (p=0.01). On the other hand, RFS by with or without uracil-tegafur as adjuvant chemotherapy in lung micropapillary-predominant or solid-predominant adenocarcinoma patients with pathological stage IA-IB disease was not significantly different.Conclusion: This study suggested that histological subtypes such as micropapillary- or solid-predominant pattern are risk factors for recurrence in pathological stage 0-I lung adenocarcinoma and may be necessary adjuvant chemotherapy instead of uracil-tegafur.
引用
收藏
页码:366 / 373
页数:8
相关论文
共 23 条
  • [1] BRINKMAN GL, 1963, AM REV RESPIR DIS, V87, P684
  • [2] Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
    Felip, Enriqueta
    Altorki, Nasser
    Zhou, Caicun
    Csoszi, Tibor
    Vynnychenko, Ihor
    Goloborodko, Oleksandr
    Luft, Alexander
    Akopov, Andrey
    Martinez-Marti, Alex
    Kenmotsu, Hirotsugu
    Chen, Yuh-Min
    Chella, Antonio
    Sugawara, Shunichi
    Voong, David
    Wu, Fan
    Yi, Jing
    Deng, Yu
    McCleland, Mark
    Bennett, Elizabeth
    Gitlitz, Barbara
    Wakelee, Heather
    [J]. LANCET, 2021, 398 (10308) : 1344 - 1357
  • [3] Cancer statistics, 2007
    Jemal, Ahmedin
    Siegel, Rebecca
    Ward, Elizabeth
    Murray, Taylor
    Xu, Jiaquan
    Thun, Michael J.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) : 43 - 66
  • [4] Clinicopathological predictors of survival in resected primary lung adenocarcinoma
    Jhala, Hiral
    Harling, Leanne
    Rodrigo, Alberto
    Nonaka, Daisuke
    Mclean, Emma
    Ng, Wen
    Okiror, Lawrence
    Bille, Andrea
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2022, 75 (05) : 310 - 315
  • [5] A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
    Kato, H
    Ichinose, Y
    Ohta, M
    Hata, E
    Tsubota, N
    Tada, H
    Watanabe, Y
    Wada, H
    Tsuboi, M
    Hamajima, N
    Ohta, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (17) : 1713 - 1721
  • [6] Prediction of survival and cancer recurrence using F-18 FDG PET/CT in patients with surgically resected early stage (Stage I and II) non-small cell lung cancer
    Kim, Y. S.
    Kim, S. J.
    Kim, Y. K.
    Kim, I. J.
    Kim, Y. D.
    Lee, M. K.
    [J]. NEOPLASMA, 2011, 58 (03) : 245 - 250
  • [7] Prognostic value of prognostic nutritional index in lung cancer: a meta-analysis
    Li, Dan
    Yuan, Xia
    Liu, Jia
    Li, Changling
    Li, Weimin
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 (09) : 5298 - 5307
  • [8] The New Histologic Classification of Lung Primary Adenocarcinoma Subtypes Is a Reliable Prognostic Marker and Identifies Tumors With Different Mutation Status
    Mansuet-Lupo, Audrey
    Bobbio, Antonio
    Blons, Helene
    Becht, Etienne
    Ouakrim, Hanane
    Didelot, Audrey
    Charpentier, Marie-Christine
    Bain, Serge
    Marmey, Beatrice
    Bonjour, Patricia
    Biton, Jerome
    Cremer, Isabelle
    Dieu-Nosjean, Marie-Caroline
    Sautes-Fridman, Catherine
    Regnard, Jean-Francois
    Laurent-Puig, Pierre
    Alifano, Marco
    Damotte, Diane
    [J]. CHEST, 2014, 146 (03) : 633 - 643
  • [9] Neutrophil-lymphocyte ratio predicts recurrence in patients with resected stage 1 non-small cell lung cancer
    Mizuguchi, Shinjiro
    Izumi, Nobuhiro
    Tsukioka, Takuma
    Komatsu, Hiroaki
    Nishiyama, Noritoshi
    [J]. JOURNAL OF CARDIOTHORACIC SURGERY, 2018, 13
  • [10] Prognostic significance of histologic subtype in pStage I lung adenocarcinoma
    Motono, Nozomu
    Matsui, Takuma
    Machida, Yuichiro
    Usuda, Katsuo
    Uramoto, Hidetaka
    [J]. MEDICAL ONCOLOGY, 2017, 34 (06)